Ascendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $313.52

Key Points

• Analyst sentiment is broadly positive: 19 of 21 analysts rate Ascendis Pharma a buy, while two recommend holding; the average 12-month price target is $313.52.
• Shares traded at $275.39, near their reported one-year high of $282.15. The company’s latest reported quarterly EPS of $1.03 missed the $1.71 consensus, although revenue topped estimates.
• Pipeline and cash-flow developments offer potential support: European regulators issued positive opinions for TransCon CNP, with a final EU decision expected in Q4 2026, and management expects at least €600 million in full-year operating cash flow.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has received an average recommendation of "Moderate Buy" from the twenty-one analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $313.52.

A number of equities analysts recently weighed in on the company. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Ascendis Pharma A/S in a report on Tuesday, October 13th. KeyCorp set a $330.00 price objective on Ascendis Pharma A/S in a report on Friday. Wedbush restated an "outperform" rating and issued a $327.00 price objective on shares of Ascendis Pharma A/S in a research report on Tuesday, September 1st. Wall Street Zen raised Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research note on Sunday, November 8th. Finally, Morgan Stanley dropped their price target on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an "overweight" rating on the stock in a research note on Tuesday, September 1st.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND traded up $8.32 during mid-day trading on Friday, reaching $275.39. 826,059 shares of the stock were exchanged, compared to its average volume of 694,460. The business's 50 day moving average is $242.67 and its 200-day moving average is $239.83. Ascendis Pharma A/S has a 1 year low of $188.08 and a 1 year high of $282.15. The company has a market capitalization of $17.18 billion, a P/E ratio of 18.00 and a beta of 0.40. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.32 and a current ratio of 2.99.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 EPS for the quarter, missing the consensus estimate of $1.71 by ($0.68). The firm had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 73.26% and a return on equity of 44.80%. On average, equities research analysts forecast that Ascendis Pharma A/S will post 3.43 EPS for the current fiscal year.

Trending Headlines about Ascendis Pharma A/S

Here are a few of the latest headlines about ASND:

• Positive Sentiment: Analyst updates lean bullish. TD Cowen raised its target to $352 and UBS lifted its target to $315, both maintaining buy ratings. Cantor Fitzgerald also raised its target to $315 with an overweight rating; RBC reaffirmed outperform at $290. These higher targets indicate continued analyst confidence in the outlook. Read More. · Read More. · Read More. · Read More.
• Positive Sentiment: Pipeline and cash-flow updates add support. European regulators issued positive opinions for TransCon CNP, with a final European Commission decision expected in Q4 2026. Management expects at least €600 million in full-year operating cash flow. Read More.
• Neutral Sentiment: Analyst views are not unanimous. Canaccord raised its target to $274 but kept a hold rating, while HC Wainwright cut its target to $335, though it retained a buy rating. Read More. · Read More.

Insider Transactions at Ascendis Pharma A/S

In other news, SVP Mads Bodenhoff sold 3,000 shares of Ascendis Pharma A/S stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $270.19, for a total value of $810,570.00. Following the sale, the senior vice president owned 3,000 shares in the company, valued at $810,570. This trade represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 40.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ascendis Pharma A/S

Hedge funds have recently modified their holdings of the business. Chicago Partners Investment Group LLC raised its position in shares of Ascendis Pharma A/S by 2.3% during the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,316 shares of the biotechnology company's stock worth $564,000 after purchasing an additional 52 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 34.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 272 shares of the biotechnology company's stock worth $62,000 after purchasing an additional 69 shares during the last quarter. Fifth Third Bancorp lifted its holdings in shares of Ascendis Pharma A/S by 48.4% in the 3rd quarter. Fifth Third Bancorp now owns 279 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 91 shares during the last quarter. ProShare Advisors LLC boosted its position in Ascendis Pharma A/S by 5.6% during the 3rd quarter. ProShare Advisors LLC now owns 2,134 shares of the biotechnology company's stock valued at $486,000 after purchasing an additional 113 shares during the period. Finally, AlphaCentric Advisors LLC boosted its position in Ascendis Pharma A/S by 2.6% during the 3rd quarter. AlphaCentric Advisors LLC now owns 4,706 shares of the biotechnology company's stock valued at $1,072,000 after purchasing an additional 121 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.